Implementation of the Massey Bedside Swallowing Screen and strict oral care regimens in high-risk patients reduced the rate of hospital-acquired pneumonia (HAP) at an oncology treatment center.
Positive results of drug Validive for prevention and treatment of severe oral mucositis in patients with head and neck cancer.
Mice that produced the Smad7 protein in the oral cavity were dramatically more resistant to radiation-induced oral mucositis than were controls.
Drugs that inhibit mammalian target of rapamycin (mTOR) stopped radiation-induced damage in mice by protecting cells crucial to tissue repair.
Thermal imaging can detect early changes in the temperature of mucosal surfaces that may signal mucositis in persons with head and neck cancer who are receiving chemoradiotherapy.
Developing an evidence-based oral care policy may help to prevent or to more effectively manage oral mucositis in oncology patients.
Oral mucositis is a common side effect of both chemotherapy and radiation that patients find distressing, yet there are interventions that seem to help.
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|